Johns Hopkins ABX Guide
Retapamulin
INDICATIONS
FDA
FDA
- Indicated for the topical treatment of impetigo due to S. aureus (MSSA) or S. pyogenes in patients >9 months old.
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- In vitro activity against MRSA, but no clinical data.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: March 7, 2019
Citation
Avdic, Edina, and Paul A Pham. "Retapamulin." Johns Hopkins ABX Guide, The Johns Hopkins University, 2019. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540474/all/Retapamulin.
Avdic E, Pham PA. Retapamulin. Johns Hopkins ABX Guide. The Johns Hopkins University; 2019. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540474/all/Retapamulin. Accessed December 12, 2024.
Avdic, E., & Pham, P. A. (2019). Retapamulin. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540474/all/Retapamulin
Avdic E, Pham PA. Retapamulin [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2019. [cited 2024 December 12]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540474/all/Retapamulin.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Retapamulin
ID - 540474
A1 - Avdic,Edina,Pharm.D.
AU - Pham,Paul,Pharm.D. BCPS
Y1 - 2019/03/07/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540474/all/Retapamulin
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
